These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16275076)

  • 1. Pyrrolopyridazine MEK inhibitors.
    Chen Z; Kim SH; Barbosa SA; Huynh T; Tortolani DR; Leavitt KJ; Wei DD; Manne V; Ricca CS; Gullo-Brown J; Poss MA; Vaccaro W; Salvati ME
    Bioorg Med Chem Lett; 2006 Feb; 16(3):628-32. PubMed ID: 16275076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors.
    Tang PC; Feng J; Huang L; Xu Z; Cheng L; Zhang X; Zhang L; Hu B
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6437-40. PubMed ID: 19815412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors.
    Fox BM; Iio K; Li K; Choi R; Inaba T; Jackson S; Sagawa S; Shan B; Tanaka M; Yoshida A; Kayser F
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6030-3. PubMed ID: 20833038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
    Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
    Tavares FX; Boucheron JA; Dickerson SH; Griffin RJ; Preugschat F; Thomson SA; Wang TY; Zhou HQ
    J Med Chem; 2004 Sep; 47(19):4716-30. PubMed ID: 15341487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR studies of diarylpyrrole anticoccidial agents.
    Qian X; Liang GB; Feng D; Fisher M; Crumley T; Rattray S; Dulski PM; Gurnett A; Leavitt PS; Liberator PA; Misura AS; Samaras S; Tamas T; Schmatz DM; Wyvratt M; Biftu T
    Bioorg Med Chem Lett; 2006 May; 16(10):2817-21. PubMed ID: 16517161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors.
    Wityak J; Hobbs FW; Gardner DS; Santella JB; Petraitis JJ; Sun JH; Favata MF; Daulerio AJ; Horiuchi KY; Copeland RA; Scherle PA; Jaffe BD; Trzaskos JM; Magolda RL; Trainor GL; Duncia JV
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1483-6. PubMed ID: 15006386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Xue Y; Arzel E; Kallin E; Magnus A; Plobeck N; Viklund J
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1397-401. PubMed ID: 16337120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1.
    Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Sim T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Ohmori O; Caldwell J; Gray N; He Y
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2173-6. PubMed ID: 16458503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
    Tecle H; Shao J; Li Y; Kothe M; Kazmirski S; Penzotti J; Ding YH; Ohren J; Moshinsky D; Coli R; Jhawar N; Bora E; Jacques-O'Hagan S; Wu J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):226-9. PubMed ID: 19019675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel 3-arylamino- and 3-cycloalkylamino-5, 6-diphenyl-pyridazines active as ACAT inhibitors.
    Toma L; Giovannoni MP; Vergelli C; Dal Piaz V; Kwon BM; Kim YK; Gelain A; Barlocco D
    Arch Pharm (Weinheim); 2002; 335(11-12):563-6. PubMed ID: 12596221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel pyrrolopyridazine scaffolds as transient receptor potential vanilloid (TRPV1) antagonists.
    Dorange I; Forsblom R; Macsari I; Svensson M; Bylund J; Besidski Y; Blid J; Sohn D; Gravenfors Y
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6888-95. PubMed ID: 23058884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies.
    Liu M; Wang S; Clampit JE; Gum RJ; Haasch DL; Rondinone CM; Trevillyan JM; Abad-Zapatero C; Fry EH; Sham HL; Liu G
    Bioorg Med Chem Lett; 2007 Feb; 17(3):668-72. PubMed ID: 17107797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro evaluation of imidazopyridazines as novel inhibitors of the malarial kinase PfPK7.
    Bouloc N; Large JM; Smiljanic E; Whalley D; Ansell KH; Edlin CD; Bryans JS
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5294-8. PubMed ID: 18774709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-cyano-6,7-dialkoxyquinolines.
    Zhang N; Wu B; Eudy N; Wang Y; Ye F; Powell D; Wissner A; Feldberg LR; Kim SC; Mallon R; Kovacs ED; Toral-Barza L; Kohler CA
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1407-10. PubMed ID: 11378365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction.
    Evans GB; Furneaux RH; Tyler PC; Schramm VL
    Org Lett; 2003 Oct; 5(20):3639-40. PubMed ID: 14507192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.